S
Selexipag
Availability of ACE Drug Guidance
Yes
Biologics Drug Information Overview
No
Subsidy Information and Financing Scheme
Medical Assistance Fund
Active ingredient: Selexipag
General information
Subsidy Information and Financing Scheme
[MAF] Selexipag Tablet 200 mcg, 400 mcg, 600 mcg, 800 mcg
To be added as the second or third drug in a combination treatment for pulmonary arterial hypertension (PAH), in line with the following criteria:
• Patient is already receiving an endothelin receptor antagonist and/or a phosphodiesterase type 5 inhibitor at maximum tolerated doses; and
• Prior to adding selexipag treatment, patient is assessed to have intermediate to high risk of 1-year mortality (according to the European Society of Cardiology/European Respiratory Society risk-stratification tool) during follow-up.
Drug Guidance for Subsidy
16/09/2025 Selexipag for treating pulmonary arterial hypertension
The Ministry of Health’s Drug Advisory Committee has recommended:
Selexipag 200 mcg, 400 mcg, 600 mcg and 800 mcg tablet, to be added as the second or third drug in a combination treatment for pulmonary arterial hypertension, in line with the following criteria:
Patient is already receiving an endothelin receptor antagonist and/or a phosphodiesterase type 5 inhibitor at maximum tolerated doses; and
Prior to adding selexipag treatment, patient is assessed to have intermediate to high risk of 1-year mortality (according to the European Society of Cardiology/European Respiratory Society risk-stratification tool) during follow-up.
Funding status
[R] Selexipag 200 mcg, 400 mcg, 600 mcg and 800 mcg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 November 2025.
[NR] Higher-strength tablets of selexipag (1,000 mcg, 1,200 mcg, 1,400 mcg and 1,600 mcg) have not been recommended for inclusion on the MAF as they are currently not marketed in Singapore.
General Availability in Public Healthcare Institution
Note:
General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.
Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration
Availability information
Formulation | Public Healthcare Institution |
|---|---|
Tablet 200 mcg |
|
Tablet 400 mcg |
|
Tablet 600 mcg |
|
Tablet 800 mcg |
|
Tablet, Film Coated 1 mg |
|
Tablet, Film Coated 1.2 mg |
|
Tablet, Film Coated 1.4 mg |
|
Tablet, Film Coated 1.6 mg |
|
Registered Product(s) Information
Clinical and product info
Clinical info | Product Info |
|---|---|
Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch. The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice. | Information available here are product details as registered with the HSA. As this website is updated monthly, please refer to HSA Infosearch for the most updated product information. |
Oral
* Clinical information is available for this product.